Compile Data Set for Download or QSAR
Report error Found 4084 Enz. Inhib. hit(s) with Target = 'P2Y purinoceptor 1'
TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359083(US10220040, Compound Va)
Affinity DataEC50:  5.52E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359084(US10220040, Compound Ih-(R-isomer))
Affinity DataEC50:  4.24E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359085(US10220040, Compound Ih-(S-isomer))
Affinity DataEC50:  3.37E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359086(US10220040, Compound IIa)
Affinity DataEC50:  4.03E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359087(US10220040, Compound IIb)
Affinity DataEC50:  2.99E+5nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359088(US10220040, Compound IIc)
Affinity DataEC50:  6.63E+6nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359089(US10220040, Compound VIIa)
Affinity DataEC50:  4.03E+7nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM359090(US10220040, Compound XIa)
Affinity DataEC50:  4.89E+4nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 13(Human)
Cerenis Therapeutics Holding

US Patent
LigandPNGBDBM50118225(ARL 69931MX | Adenosine triphosphate derivative | ...)
Affinity DataEC50:  6.32E+3nMAssay Description:Compounds were assayed for their agonist activity on P2Y13 GPCR transfected cells using a Ca++ flux assay (associated to fluorescent dye detection) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21079(1-[4-(3-azanyl-1H-indazol-4-yl)phenyl]-3-(2-fluora...)
Affinity DataKd:  3.90E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM31085(cid_11409972 | 1-[4-[(4-ethylpiperazin-1-yl)methyl...)
Affinity DataKd:  1.40E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM31095(5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-yli...)
Affinity DataKd:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM31096(CHEMBL290084 | Staurosporine | cid_451705 | US2024...)
Affinity DataKd:  81nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM4814(SUNITINIB MALATE | CHEMBL535 | N-[2-(diethylamino)...)
Affinity DataKd:  430nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 14(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM13534(VX680 | N-[4-[[4-(4-methylpiperazino)-6-[(5-methyl...)
Affinity DataKd:  290nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000935(CHEMBL91204 | 7-(5-Oxo-5-piperidin-1-yl-pentyl)-1,...)
Affinity DataEC50:  420nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000867(CHEMBL91359 | 7-(4-Hydroxy-pentyloxy)-1,3-dihydro-...)
Affinity DataEC50:  100nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000880(CHEMBL90195 | 7-(2-Hydroxy-ethoxy)-1,3-dihydro-imi...)
Affinity DataEC50:  20nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000891(CHEMBL88764 | 5-(1-Methyl-2-oxo-2,3-dihydro-1H-imi...)
Affinity DataEC50:  540nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000915(CHEMBL431799 | 5-(2-Oxo-2,3-dihydro-1H-imidazo[4,5...)
Affinity DataEC50:  1nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000868(CHEMBL88444 | {Cyclohexyl-[4-(2-oxo-2,3-dihydro-1H...)
Affinity DataEC50:  20nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000868(CHEMBL88444 | {Cyclohexyl-[4-(2-oxo-2,3-dihydro-1H...)
Affinity DataEC50:  20nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000887(CHEMBL88707 | 5-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  1.07E+3nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000907(CHEMBL92269 | 4-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  600nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000885(CHEMBL91843 | 5-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  950nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000896(CHEMBL89876 | Acetic acid 2-(2-oxo-2,3-dihydro-1H-...)
Affinity DataEC50:  870nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000923(CHEMBL92158 | Acetic acid 4-(2-oxo-2,3-dihydro-1H-...)
Affinity DataEC50:  950nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000927(CHEMBL88108 | {Cyclohexyl-[4-(2-oxo-2,3-dihydro-1H...)
Affinity DataEC50:  9.60E+3nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000924(CHEMBL90102 | 4-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H...)
Affinity DataEC50: >8.75E+4nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000883(CHEMBL313282 | 1-Methyl-7-(4-oxo-4-piperidin-1-yl-...)
Affinity DataEC50:  1.09E+4nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000913(CHEMBL314763 | 7-(2,3-Dihydroxy-propoxy)-1,3-dihyd...)
Affinity DataEC50:  260nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000926(CHEMBL91899 | 7-(2-Ethoxy-ethoxy)-1,3-dihydro-imid...)
Affinity DataEC50:  4.84E+3nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000881(CHEMBL90881 | 4-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  590nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000933(CHEMBL92264 | N-Adamantan-1-yl-4-(2-oxo-2,3-dihydr...)
Affinity DataEC50:  20nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000895(CHEMBL91579 | 4-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H...)
Affinity DataEC50:  9.41E+3nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000874(CHEMBL88377 | 5-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  1.32E+3nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000930(CHEMBL421885 | 4-(1-Methyl-2-oxo-2,3-dihydro-1H-im...)
Affinity DataEC50: >1.06E+5nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000906(CHEMBL89660 | 7-(4-Morpholin-4-yl-4-oxo-butoxy)-1,...)
Affinity DataEC50:  280nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000879(CHEMBL89679 | 7-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)...)
Affinity DataEC50:  250nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000934(CHEMBL91127 | 3-(2-Oxo-2,3-dihydro-1H-imidazo[4,5-...)
Affinity DataEC50:  440nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000871(CHEMBL69139 | N-Cyclohexyl-N-methyl-4-(2-oxo-1,2,3...)
Affinity DataEC50:  440nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000877(CHEMBL88955 | N-Cycloheptyl-N-methyl-4-(2-oxo-2,3-...)
Affinity DataEC50:  60nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000928(CHEMBL91044 | 5-(1-Methyl-2-oxo-2,3-dihydro-1H-imi...)
Affinity DataEC50:  150nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000878(CHEMBL88835 | 7-[3-(1H-Tetrazol-5-yl)-propoxy]-1,3...)
Affinity DataEC50: >1.00E+5nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000901(CHEMBL91634 | 4-(1-Methyl-2-oxo-2,3-dihydro-1H-imi...)
Affinity DataEC50:  1.90E+3nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000925(7,8-Dimethyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-...)
Affinity DataEC50:  390nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000900(CHEMBL90804 | {Cyclohexyl-[4-(2-oxo-2,3-dihydro-1H...)
Affinity DataEC50:  6nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000895(CHEMBL91579 | 4-(1,3-Dimethyl-2-oxo-2,3-dihydro-1H...)
Affinity DataEC50: >1.00E+5nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000888(CHEMBL90168 | N-Methyl-4-(2-oxo-2,3-dihydro-1H-imi...)
Affinity DataEC50:  1.33E+3nMAssay Description:Inhibition of platelet aggregation using Adenosine diphosphate (ADP) as activating agent in rabbit platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetP2Y purinoceptor 12(Human)
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50000897(CHEMBL90414 | 7-(4-Oxo-4-piperidin-1-yl-butoxy)-1,...)
Affinity DataEC50:  130nMAssay Description:Inhibition of platelet aggregation using adenosine diphosphate (ADP) as activating agent in human platelet rich plasma (PRP)More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Displayed 1 to 50 (of 4084 total ) | Next | Last >>
Jump to: